Goldman Sachs analyst Isaac Ro issued an after-hours note Tuesday commenting on intra-day price action in EXACT Sciences
Corporation (NASDAQ: EXAS).
With EXACT shares up more than 30 percent over the session, Ro noted "an updated USPSTF website which could have bearing on
future reimbursement of Cologuard."
Related Link: Exact Sciences Continues
Mysterious Rally
The analyst said, "We take no position on the Final Recommendation and potential financial impact to EXAS but note the timing
comes sooner than expected. If Cologuard were included as a recommended screening method we would view the news as a positive for
EXAS shares."
Ro maintained a Neutral rating on shares.
Latest Ratings for EXAS
| Date |
Firm |
Action |
From |
To |
| May 2016 |
Mizuho Securities |
Downgrades |
Buy |
Neutral |
| Feb 2016 |
Empire Asset Management |
Maintains |
|
Sell |
| Feb 2016 |
Roth Capital |
Downgrades |
Buy |
Neutral |
View More Analyst Ratings for
EXAS
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.